1 / 53

Evidence-Based Medicine ACE-Inhibitor and ARB; combination therapy

Evidence-Based Medicine ACE-Inhibitor and ARB; combination therapy. Assess. 64 year old Hispanic male with history of DMII, HTN, HLD and CAD, presents to nephrology clinic for chronic renal insufficiency follow up. Patient with well controlled diabetes, hyperlipidemia and hypertension.

odele
Download Presentation

Evidence-Based Medicine ACE-Inhibitor and ARB; combination therapy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Evidence-Based MedicineACE-Inhibitor and ARB; combination therapy

  2. Assess • 64 year old Hispanic male with history of DMII, HTN, HLD and CAD, presents to nephrology clinic for chronic renal insufficiency follow up. • Patient with well controlled diabetes, hyperlipidemia and hypertension. • Physical exam is unremarkable, no peripheral neuropathy or documented retinopathy.

  3. Assess • Medication regimen • Asprin 325mg daily • Plavix 75mg daily • Lisinopril 40mg daily • Lopressor 25mg twice a day • Nifedipine ER 30mg daily • Lipitor 80mg daily • Glipizide 5mg • Actos 45mg

  4. Assess • Lab • GFR • Serum creatinine of 2.3mg per deciliter • Microalbumin/Creatinine 384

  5. ASK • Diabetic nephropathy • Preventing progression • Decreasing risk factors for cardiovascular event • ACE-Inhibitor and ARB combination • Decrease proteinuria • Would patient benefit from combination therapy? • Decreasing risk for cardiovascular events?

  6. ASK • P- A patient with DMII, CAD and CKD. • I- Addition of ARB to ACE-Inhibitor therapy. • C- ACE-Inhibitor monotherapy • O- decreased incidence of cardiovascular events.

  7. ASK • Over the last 16 years effects of ACE-Inhibitors have been extensively documented. • Two trials in 2003 compared combination therapy of ACE-Inhibitor and ARB to ACE-Inhibitor monotherapy, in patients with CHF and acute MI. • Trial in 2008 compared combination therapy to ACE-Inhibitor monotherapy in patients with vascular disease or high-risk diabetes.

  8. Acquire • PubMed • Search: PubMed • For: ACEI and ARB combination therapy • EBM review • ACP Journal Club, Cochrane, • Keyword: ACEI and ARB combination therapy

  9. Acquire • NMCSD homepage (nmcsdintranet) • Reference Material • Medline/OVI • Library homepage • Journals • NEJM • Lancet • Databases • PubMed@NMCSD • EBM reviews

  10. Appraise • Effects of candersartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin converting enzyme inhibitor: the CHARM Added trial. • J McMurray, J Ostergren, P Swedberg et al., The Lancet 362 (2003), pp 767-771. • Reduction in cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction with the addition of angiotensin II type 1 receptor blocker to angiotensin converting enzyme-inhibitor monotherapy.

  11. CHARM-Added trial • Between March 1999 and November 1999, eligible patients in 618 centers in 26 countries were enrolled. • Ages 18 years old or greater • left ventricular ejection fraction less then 40% or lower • measured within the past 6 months • NYHA functional class II-IV • Treatment with an ACE-inhibitor at a constant dose of 30 days or longer. • Patients were randomly assigned to candesartan or matching placebo group.

  12. CHARM-Added trial • Treatment (double-blind) • starting dose was 4mg/8mg daily • dose was doubled every 2 weeks, as tolerated. • Blood pressure, serum creatinine and Potassium. • Target dose was 32mg once daily • starting from 6 weeks. • Follow-up • 2, 4, 6 weeks, at 6 months and, thereafter at every 4 months until the end of the trial.

  13. CHARM-Added Trial

  14. CHARM-Added trial • 2548 patients enrolled • 1276 candesartan group • 1272 placebo group • Enalapril, lisinopril, captopril and ramipril. • Similar dosing in in both groups • Beta-blocker • 64% candesartan, 68% placebo • Spirnolactone • 20% candesartan, 25% placebo

  15. CHARM-Added trial

  16. CHARM-Added trial

  17. CHARM-Added trail • Results • 483 (38%) patients in candesartan and 538 (42%) in the placebo group experienced primary outcome of cardiovascular death or admission to hospital for CHF. • Unadjusted hazard ratio 0.85 (95% CI 0.75-0.96) • p= 0.011 • Covariate adjustment p= 0.010 • Candesartan reduced cardiovascular mortality and the risk of admission to hospital for CHF. • 302 (24%) CV deaths in candersartan, 347 (27%) in the placebo group. • p= 0.029 • Covariant adjustment p= 0.021

  18. CHARM-Added trial

  19. CHARM-Added trial

  20. CHARM-Added trial

  21. CHARM-Added Trial • Discussion • Possible cardiovascular benefit of ACE-Inhibitor and ARB combination therapy. • Increase in adverse events

  22. Appraise • Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (VALIANT) • M Pfeffer, J Mcmurray, E Velasquez et al., NEJM 2004;350(2): 203 • Effects of ARB, ACE-Inhibitor monotherapy and combination therapy in death from any cause, after acute myocardial infarction.

  23. VALIANT • 14,808 eligible patients were enrolled between December 1998 through June 2001 from 931 centers in 24 countries. • Men and Women 18 years of age or older who had acute MI (between 0.5 and 10 days previously) that was complicated by clinical or radiological signs of heart failure • Evidence of left ventricular systolic dysfunction (an ejection fraction <0.35 on echocardiogram or contrast angiography and <0.40 radionuclide ventriculography) • At randomization • SBP >100mm Hg • Serum Creatinine of less then 2.5mg per decilitir • Contraindication • Previous intolerance or contraindication to an ACE-Inhibitor or ARB. • Clinically significant valvular disease • Disease known to limit life expectancy severely • Absence of written informed consent

  24. VALIANT • Randomly assigned in a 1:1:1 ratio • Valsartan monotherapy, 4909 • Valsartan plus captopril, 4885 • Captopril monotherapy, 4909 • Patient was unaware of regimen, independent drug- distribution group and although data processing and site management and analysis was performed by one identity, only data and safety monitoring board in this identity was aware of treatment-group assignments.

  25. VALIANT

  26. VALIANT

  27. VALIANT

  28. VALIANT • Therapy • Initial • 20mg Valsartan, 20mg Valsartan and 6.25mg of Captopril, or 6.5mg Captopril. • Dose increased in four steps • goal of 80mg Valsartan, 40mg Valsartan bid and 25mg of Captopril tid, or 25mg of Captopril tid while in the hospital • goal 160mg Valsartan, 80mg Valsartan bid, and 50mg Captopril tid, , or 50mg Captopril tid by three month visit. • Follow-Up • Study visits took place 6 times during the first year and at 4 month intervals thereafter.

  29. VALIANT • RESULTS • All but 77 (0.5%) patients received study medications. • Median duration of follow up 24.7 months • 139 (0.9%) patients were lost to follow up or withdrew consent

  30. VALIANT • Results • Mortality • Similar in three treatment groups • Hazard ratio for death 1.00 (p=0.98) Valsartan vs Captopril and 0.98 (p=0.73) Captopril vs combination. • Cardiovascular Morbidity and Mortality • Similar in three treatment group

  31. VALIANT

  32. VALIANT • Comparing VALIANT

  33. VALIANT • Results • Noninferiority of Valsartan • Mortality • Intention-to-treat • Pre- protocol population • Tolerability and Safety • No longer taking medication at one year • 15.3% Valsartan, 19.0% combination, 16.8 Captopril • Dose at one year • At three month goals

  34. VALIANT • Tolerability and Safety (continued) • Discontinuation • Own decision • Adverse events • Highest rate occurring in valsarten-and-captopril group

  35. VALIANT

  36. VALIANT • Discussion • Improved survival and reduced rates of major nonfatal cardiovascular events • No added benefit in combination therapy • Combination therapy had increased adverse events.

  37. Appraise • Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events • The ONTARGET Investigators • NEJM 2008; 350 (2):1547-1559 • Effects of ARB, ACE-Inhibitors, combination therapy in death from cardiovascular causes, MI, stroke, or hospitalization for heart failure.

  38. 29,019 patients were recruited from 733 centers in 40 countries. Single-Blind run in-period 2.5mg ramipril daily x 3days 40mg telmisartan and 2.5mg ramipril daily x 7 days 5mg ramipril and 40mg telmisartan x 11-18 days 3399 (11.7%) patients were excluded Poor compliance (3.9%) Withdrew from study(2.1%) Symptomatic hypotension(1.7%) Elevated K level (0.8%) Elevated serum creatinine level(0.2%) Other (3.0%) Death(0.1%) ONTARGET

  39. ONTARGET • 25,620 patients underwent randomization • 8542 patients received 80mg telmisartan daily • 8576 patients received 5mg ramipril daily • 8502 patients received combination therapy • After two weeks dose of ACE-Inhibitor was increased to 10mg daily.

  40. ONTARGET • Follow up • 25577 (99.8%) patients were followed until primary event occurred or until the end of the study (median, 56months). • At 2 years, 81.7% of Ramipril group was receiving full dose, 75.3% in combination group. • At 2 years, 88.6% of Telmisartan group was receiving full dose, 84.3% in combination group. • 2029 patients (23.7%) in Ramipril group and 1796 (21.0%) in Telmisartan group discontinued the study drug (combination group, 22.7%)

  41. ONTARGET

  42. ONTARGET • Blood pressure • Telmisartin and combination group maintained slightly lower blood pressure levels. • Serum Creatinine • Number of patients with increased levels was similar in three groups. • Potassium • Similar number of patients with levels more then 5.5 mmmol per liter in monotherapy groups. (283/287) • Significantly higher levels in combination group • 480 patients • p=<0.001

  43. ONTARGET • Primary Outcomes • 1412 (16.5%) in Ramipril group, • 1423 (16.7%) patients in Telmisartan group • 1386 (16.3) patients in combination group • Telmisartan was noninferior to Ramipril, nor was it superior • Upper boundary of CI for RR of primary outcome was lower then predetermined (noninferiority) • Lower boundary of CI (not superior) • No significant difference in total number of deaths between mono therpay groups. • Higher number of deaths in combination group, but not statistically significant.

  44. ONTARGET

  45. Kaplan-Meier Curves for the Primary Outcome in the Three Study Groups

  46. ONTARGET

  47. ONTARGET • Patients who have vascular disease or high risk diabetes, Telmisartan is equally effective to Ramipril. • No additional benefit from combination therapy

More Related